ID: hyp-sda-2026-04-01-001-1
Hypothesis
APOE-TREM2 Synergistic Modulation
Dual APOE mimetic and TREM2 co-activator therapy leveraging the strong APOE-TREM2 interaction (score: 0.986) for microglial lipid metabolism and amyloid clearance.
EvidencePending (0%)📖 5 cit🗣 1 debates✓ 5 support✗ 1 oppose
✓ All Quality Gates Passed
🧪 Overview
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["APOE e4 Isoform<br/>Reduced TREM2 Binding Affinity"]
B["TREM2 Lipid Sensing Impaired<br/>Microglial Lipid Metabolism Deficit"]
C["APOE Mimetic Peptide<br/>Restores APOE-TREM2 Interaction"]
D["TREM2 Co-Activator Compound<br/>Receptor Stabilization and Signaling"]
E["Dual Therapy Synergy<br/>APOE Mimetic plus TREM2 Co-Activator"]
F["Microglial Cholesterol Efflux Restored<br/>Lipid Droplet Burden Reduced"]
G["Amyloid-Beta Phagocytosis Enhanced<br/>Plaque Clearance Improved"]
H["Neuroinflammation Resolved<br/>AD Neuroprotection"]
A --> B
C --> E
D --> E
E --> F
E --> G
F --> H
G --> H
style E fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style H fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix5 supports0 contradicts
Supports
TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways.
Supports
ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies.
Supports
APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer's disease.
Supports
The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases.
Supports
Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — ['APOE'
No curated PDB or AlphaFold mapping for ['APOE' yet. Search RCSB →
💉 Clinical Trials (5)
0
Active
Active
0
Completed
Completed
0
Total Enrolled
Total Enrolled
PHASE2
Highest Phase
Highest Phase
TERMINATED·NCT00550420 · GlaxoSmithKline
Alzheimer's Disease
Rosiglitazone XR
NOT_YET_RECRUITING·NCT06682767 · Cedars-Sinai Medical Center
Cerebral Blood Flow APOE 4
FMD1 (LNT22-017-1) Dietary Guidance
RECRUITING·NCT07146412 · HudsonAlpha Institute for Biotechnology
Cognitive Impairment Alzheimer Blood Biomarkers Alzheimer Disease (AD)
Multimodal Lifestyle Intervention
COMPLETED·NCT01928420 · Humanetics Corporation
Alzheimer's Disease Dementia
Drug: NIC5-15 Placebo
COMPLETED·NCT01741194 · Cerecin
Alzheimer's Disease
AC-1204 Placebo
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for ['APOE', 'TREM2'].
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0580
Events (7d)
1
Price History
▼8.2%💾 Resource Usage
LLM Tokens
14,692
$0.0882
Total Cost
$0.0882
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF iPSC-derived microglia from APOE4/4 carriers are treated with combined APOE mimetic (1 μM COG1410) and TREM2 agonistic antibody (10 μg/mL) for 72 hours during exposure to fluorescently-labeled Aβ42 | ≥40% reduction in internalized Aβ42 fluorescence and ≥50% increase in lipid droplet area per microglia cell | — no observation — | pending | 0.00 |
| IF aged 5xFAD mice (8 months) receive combined intraperitoneal APOE mimetic peptide (COG1410, 2 mg/kg) and TREM2-activating antibody (2 mg/kg, biweekly) for 12 weeks, THEN amyloid plaque coverage in c | ≥30% reduction in amyloid plaque area fraction in cortical and hippocampal regions after 12-week combination treatment | — no observation — | pending | 0.00 |
🔮 Falsifiable Predictions (2)
pendingconf 0%
IF aged 5xFAD mice (8 months) receive combined intraperitoneal APOE mimetic peptide (COG1410, 2 mg/kg) and TREM2-activating antibody (2 mg/kg, biweekly) for 12 weeks, THEN amyloid plaque coverage in cortex and hippocampus will decrease by ≥30% compared to vehicle-treated 5xFAD mice as measured by th
Predicted outcome: ≥30% reduction in amyloid plaque area fraction in cortical and hippocampal regions after 12-week combination treatment
Falsification: No significant reduction (p>0.05) or increase in amyloid plaque burden in treatment group versus vehicle controls at 12-week endpoint
pendingconf 0%
IF iPSC-derived microglia from APOE4/4 carriers are treated with combined APOE mimetic (1 μM COG1410) and TREM2 agonistic antibody (10 μg/mL) for 72 hours during exposure to fluorescently-labeled Aβ42 oligomers, THEN intracellular Aβ42 fluorescence intensity will decrease by ≥40% and lipid droplet a
Predicted outcome: ≥40% reduction in internalized Aβ42 fluorescence and ≥50% increase in lipid droplet area per microglia cell
Falsification: No significant change (p>0.05) in Aβ42 clearance or lipid droplet accumulation in APOE4/4 microglia after combination treatment versus single-agent or vehicle controls
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesis
| source | v1_phase_c_backfill |
| origin_type | debate_synthesis |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.